NR4A1 and metabolic syndrome: Several studies have shown that treatment with NR4A1 inactivators and the knockdown of NR4A1 and CTNNB1 induced ROS-ER stress-dependent apoptosis through the downregulation of TXNDC5 expression in pancreatic cancer, a devastating disease with many risk factors including pancreatitis, obesity and metabolic syndrome [71,159,160,161,162].